Inter-individual differences in drug response are an important cause of failure in anticancer treatment
and adverse drug events in cancer patients. Gene polymorphisms related to these outcomes have been investigated
in an effort to find new genetic biomarkers to predict toxicity and response to anticancer drugs. Evaluating the
value single nucleotide polymorphisms (SNPs) in the genes involved in transportation, activation and metabolism
of anticancer drugs provides a promising approach to select the appropriate therapeutic regimes with at least
adverse reactions. This review summarizes the current knowledge about the relationship between of SNPs involved
in the transportation, activation and metabolism of anticancer drugs and treatment outcomes in colorectal
cancer (CRC) patients.
Keywords: Colorectal cancer, polymorphisms, anticancer drugs, pharmacogenetics, gene polymorphisms, single nucleotide polymorphisms.
Rights & PermissionsPrintExport